OPG Rabbit Polyclonal Antibody($99/20μL)

OPG Rabbit Polyclonal Antibody($99/20μL)

Cat: APRab15357
Size:20μL Price:$99
Size:50μL Price:$118
Size:100μL Price:$220

Size:200μL Price:$380
Application:WB,IHC,ICC/IF,ELISA

Reactivity:Human,Mouse
Conjugate:Unconjugated
Optional conjugates: Biotin, FITC (free of charge).
See other 26 conjugates.

Gene Name:TNFRSF11B Category: Polyclonal Antibody Tags:

Summary

Production Name

OPG Rabbit Polyclonal Antibody

Description

Rabbit polyclonal Antibody

Host

Rabbit

Application

WB,IHC,ICC/IF,ELISA

Reactivity

Human,Mouse

 

Performance

Conjugation

Unconjugated

Modification

Unmodified

Isotype

IgG

Clonality

Polyclonal

Form

Liquid

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Buffer

Liquid in PBS containing 50% glycerol, 0.5% protective protein and 0.02% New type preservative N.

Purification

Affinity purification

 

Immunogen

Gene Name

TNFRSF11B

Alternative Names

TNFRSF11B; OCIF; OPG; Tumor necrosis factor receptor superfamily member 11B; Osteoclastogenesis inhibitory factor; Osteoprotegerin;TR11B

Gene ID

4982

SwissProt ID

O00300

 

Application

Dilution Ratio

WB 1:500-1:2000,IHC 1:100-1:300,ICC/IF 1:100-1:300,ELISA 1:10000-1:20000

Molecular Weight

55kDa

 

Background

The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. [provided by RefSeq, Jul 2008],disease:Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also called hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.,function:Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.,induction:Up-regulated by increasing calcium-concentration in the medium and estrogens. Down-regulated by glucocorticoids.,PTM:N-glycosylated. Contains sialic acid residues.,PTM:The N-terminus is blocked.,similarity:Contains 2 death domains.,similarity:Contains 4 TNFR-Cys repeats.,subunit:Homodimer.,tissue specificity:Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.,

 

Research Area

Cytokine-cytokine receptor interaction;